title: Immune alterations in untreated and treated multiple myeloma.
abstract: The incidence of second malignancies was shown to be increased in patients with multiple myeloma. Although a shared genetic predisposition or common environmental carcinogens may account for the occurrence of both myeloma and additional cancers, multiple immune defects encountered in myeloma might play an important role in this regard. This review explores the impairments in both cellular and humoral mediated immunity in multiple myeloma, linking them with increased susceptibility to infections and additional cancers. In addition, the recent therapeutic advances transformed myeloma into a chronic entity, with multiple relapses and salvage therapies, which may result in cumulative immunosuppression. Although recent reports have suggested an increased rate of second cancers in myeloma patients treated with lenalidomide, the true impact of this agent and other novel anti-myeloma therapies on the incidence of additional malignancies remains to be clarified.
authors.affiliation: Department of Hematology-Oncology, St. Francis Hospital and Medical Center, Hartford, CT, USA. c_dasanu@yahoo.com
authors.forename: Constantin A
authors.initials: CA
authors.lastname: Dasanu
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D016207:Cytokines / Q000235:genetics; D020022:Genetic Predisposition to Disease; D006801:Humans; D007111:Immunity, Cellular / Q000235:genetics*; D056724:Immunity, Humoral / Q000235:genetics*; D008297:Male; D009101:Multiple Myeloma / Q000235:genetics / Q000276:immunology* / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic / Q000379:methods / Q000639:trends
chemical_list: D016207:Cytokines